High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

被引：0
|
作者：
Christopher Nyakutira
Daniel Röshammar
Emmanuel Chigutsa
Prosper Chonzi
Michael Ashton
Charles Nhachi
Collen Masimirembwa
机构：
[1] African Institute of Biomedical Science and Technology (AiBST),Department of DMPK & BAC
[2] University of Zimbabwe,Department of Clinical Pharmacology, School of Health Sciences
[3] Sahlgrenska Academy at Göteborg University,Department of Pharmacology
[4] University of Zimbabwe,School of Pharmacy
[5] Harare City Council Health Services,undefined
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Efavirenz; HIV/AIDS patients; CYP2B6 polymorphism; Pharmacokinetic modelling; NONMEM;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：357 / 365
页数：8
相关论文
共 50 条
  • [1] High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe
    Nyakutira, Christopher
    Roshammar, Daniel
    Chigutsa, Emmanuel
    Chonzi, Prosper
    Ashton, Michael
    Nhachi, Charles
    Masimirembwa, Collen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) : 357 - 365
  • [2] Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children
    M. Viljoen
    M. O. Karlsson
    T. M. Meyers
    H. Gous
    C. Dandara
    M. Rheeders
    European Journal of Clinical Pharmacology, 2012, 68 : 339 - 347
  • [3] Distribution of CYP2B6 516G/T pharmacogenetically important polymorphism in the Ukrainian population
    Filiptsova, Olga
    Kobets, Marina
    Kobets, Julia
    Naboka, Olga
    Koiro, Olga
    Ochkur, Alexandr
    Galiy, Larisa
    SAUDI PHARMACEUTICAL JOURNAL, 2018, 26 (05) : 651 - 655
  • [4] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Milcah Dhoro
    Simbarashe Zvada
    Bernard Ngara
    Charles Nhachi
    Gerald Kadzirange
    Prosper Chonzi
    Collen Masimirembwa
    BMC Pharmacology and Toxicology, 16
  • [5] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Dhoro, Milcah
    Zvada, Simbarashe
    Ngara, Bernard
    Nhachi, Charles
    Kadzirange, Gerald
    Chonzi, Prosper
    Masimirembwa, Collen
    BMC PHARMACOLOGY & TOXICOLOGY, 2015, 16
  • [6] Occurrence of CYP2B6 516G>T polymorphism in patients with ARV-associated hepatotoxicity
    Singh, HariOm
    Lata, Sonam
    Dhole, T. N.
    Gangakhedkar, Raman R.
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2019, 7 (04):
  • [7] IMPLICATIONS OF SCREENING FOR CYP2B6 516G>T SNP ON HIV/AIDS PATIENTS
    Swart, M.
    Dandara, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 163 - 164
  • [8] Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
    Verena Gounden
    Chantal van Niekerk
    Tracy Snyman
    Jaya A George
    AIDS Research and Therapy, 7
  • [9] Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children
    Viljoen, M.
    Karlsson, M. O.
    Meyers, T. M.
    Gous, H.
    Dandara, C.
    Rheeders, M.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (04) : 339 - 347
  • [10] Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism
    Saitoh, Akihiko
    Fletcher, Courtney V.
    Brundage, Richard
    Alvero, Carmelita
    Fenton, Terrence
    Hsia, Karen
    Spector, Stephen A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (03) : 280 - 285
12345